Table 1

Characteristics of the study population

Discovery
cohort
(n=53)
No (%)
Confirmation
cohort
(n=126)
No (%)
Validation
cohort
(n=158)
No (%)
Age (years)
 ≤6031 (58)45 (35.7)45 (28.5)
 >6022 (42)81 (64.3)113 (71.5)
Gender
 Female21 (40)49 (38.9)53 (33.5)
 Male32 (60)77 (61.1)105 (66.5)
BRAF mutational status
 Negative37 (70)77 (61.1)100 (63.3)
 Positive16 (30)46 (36.5)57 (36.1)
 Unknown0 (0)3 (2.4)1 (0.6)
No of organs involved
 17 (13)15 (11.9)32 (20.3)
 215 (28)40 (31.7)35 (22.2)
 314 (26)26 (20.6)43 (27.2)
 47 (13)19 (15.1)34 (21.5)
 57 (13)14 (11.1)6 (3.8)
 62 (4)7 (5.6)7 (4.4)
 ≥71 (2)5 (4.0)1 (0.6)
AJCC M stage (AJCC 2009)
 M01 (2)3 (2.4)8 (5.1)
 M1a2 (4)4 (3.2)10 (6.3)
 M1b8 (15)20 (15.9)27 (17.1)
 M1c42 (79)99 (78.6)113 (71.5)
Visceral metastasis
 No14 (26)42 (33.3)66 (41.8)
 Yes39 (74)84 (66.7)92 (58.2)
CNS metastasis
 No38 (72)81 (64.3)126 (79.7)
 Yes15 (28)45 (35.7)32 (20.3)
Liver metastasis
 No36 (68)91 (72.2)111 (70.3)
 Yes17 (32)35 (27.8)47 (29.7)
Prior treatment regimens
 Anti-CTLA-436 (68)54 (42.9)51 (32.3)
 Anti-PD-10 (0)4 (3.2)11 (7.0)
 BRAFi±MEKi10 (19)34 (27.0)29 (18.4)
 MEKi3 (6)0 (0.0)4 (2.5)
 Chemotherapy9 (17)28 (22.2)15 (9.5)
 Radiotherapy29 (55)53 (42.1)40 (25.3)
 Adjuvant interferon17 (32)49 (38.9)31 (19.6)
 Other1 (2)1 (0.8)1 (0.6)
Line of treatment
 First line12 (23)48 (38.1)87 (55.1)
 Second line24 (45)40 (31.7)39 (24.7)
 ≥Third line17 (32)38 (30.2)32 (20.3)
  • AJCC 2009 refers to the AJCC staging guideline for melanoma from 2009.

  • AJCC, American Joint Committee on Cancer; BRAFi, BRAF inhibitors; CNS, central nervous system; CNS, central nervous system; PD-1, programmed death receptor-1.